The medical community and the public have been buffeted by asteady stream of news linking the use of widely prescribed medicationswith serious health risks. The latest in this barrage of unsettlingreports is an article by Park-Wyllie et al. that appears elsewherein this issue of the Journal1 regarding the association of thefluoroquinolone gatifloxacin with dysglycemia.
The authors describe the findings of two population-based, nestedcase–control studies involving outpatients 66 years ofage or older who had received treatment with various broad-spectrumantibiotics. The first study demonstrated a substantial increasein the risk of emergency department treatment . . . [Full Text of this Article]
Source Information
From the Meyers Primary Care Institute, a joint endeavor of the University of Massachusetts Medical School, the Fallon Clinic Foundation, and the Fallon Community Health Plan — all in Worcester, Mass.
This article was published at www.nejm.org on March 1, 2006.
This article has been cited by other articles:
Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W.
(2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med
167: 1041-1049
[Abstract][Full Text]
Beckley, E. T.
(2006). Gatifloxacin Linked to Dangerously High and Low Blood Glucose. DOC News
3: 8-8
[Full Text]
Previous
